Intracavitary chromic phosphate (32P) colloidal suspension therapy

Cancer. 1981 Dec 15;48(12):2596-8. doi: 10.1002/1097-0142(19811215)48:12<2596::aid-cncr2820481210>3.0.co;2-j.

Abstract

Two-hundred-eighty-nine patients received treatment with chronic phosphate (32P) colloidal suspension (CPCS) 346 times since 1963. One-hundred-seventy-eight patients received 200 intraperitoneal treatments. One-hundred-fifteen patients received 144 intrapleural treatments. Six patients received both intraperitoneal and intrapleural treatments. Two patients received two intrapericardial treatments. Results of therapy were evaluated three months later and then at yearly intervals. In those patients who survived three months, the referring physician observed improvement in 85% of intraperitoneal treatment and in 75% of intrapleural treatments.

MeSH terms

  • Brachytherapy*
  • Chromium / therapeutic use*
  • Chromium Compounds*
  • Follow-Up Studies
  • Humans
  • Male
  • Neoplasms / complications
  • Neoplasms / radiotherapy*
  • Peritoneal Diseases / complications
  • Peritoneal Diseases / radiotherapy
  • Peritoneum
  • Phosphates / therapeutic use*
  • Phosphorus Radioisotopes / therapeutic use*
  • Pleura
  • Pleural Effusion / complications
  • Pleural Effusion / radiotherapy

Substances

  • Chromium Compounds
  • Phosphates
  • Phosphorus Radioisotopes
  • Chromium
  • chromic phosphate